April 1, 2005
Rapamycin Analog Boosts Cisplatin's Antitumor EffectivenessTopics: Medicine
When I first spoted this article it reminded me of the early days of immunotherapy when it was found that small doses of chemotherapeutic drugs actually initiated an immune response to the tumor by affecting the selective kill of T-suppressor cells. It was later found that the DNA of the suppressor cells, being more active in certain patient populations, was more labile than the T-helper cells that had been suppressed and were less active. However, different story, different time. Today we have this promising news for anyone having to experience the very toxic effects of Cisplatin, with researchers(in-vitro study) reporting that a rapamycin derivative now in phase II trials for treating advanced cancer sensitizes tumor cells to the apoptotic effect of cisplatin :
(...) Theoretically, the findings mean cancer patients could be treated effectively with cisplatin doses 10- to 100-fold lower than those currently in clinical use, Dr. George Thomas told Reuters Health.
(...) The drug's cytostatic properties have raised the possibility that it might sensitize cells to DNA damaging agents
(...) sporadic results in the literature suggested this
might be going on, but the data was pretty poor,"
(...) "the confusion was over the concentration at which cisplatin was operating."
(...) the rapamycin derivative RAD001 indeed boosted cisplatin-induced apoptosis in tumor cell lines with wild-type 53, which represent about half of all tumors, but did not affect how tumor cells with mutant p53 responded. And the effect was only seen at low doses of cisplatin.
(...) the drug prevented p53-induced expression of p21, a cell cycle progression inhibitor that when functioning normally allows for DNA damage repair.
Posted by Hyscience at April 1, 2005 10:21 AM
Articles Related to Medicine:
- Rapamycin Analog Boosts Cisplatin's Antitumor Effectiveness - Apr 01, 2005